Enlivex Therapeutics Ltd
ENLV
查看详细走势图
0.835USD
+0.003+0.40%
收盘 12/19, 16:00（美东）报价延迟15分钟
20.28M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.40%
5天
-10.12%
1月
-8.50%
6月
-23.40%
今年开始到现在
-28.64%
1年
-32.67%
查看详细走势图
TradingKey Enlivex Therapeutics Ltd股票评分
单位: USD 更新时间: 2025-12-19操作建议
Enlivex Therapeutics Ltd当前公司基本面数据相对谨慎，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名193/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.00。中期看，股价处于下降通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Enlivex Therapeutics Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
7.000
目标均价
+536.36%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Enlivex Therapeutics Ltd亮点
亮点风险
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Enlivex Therapeutics Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Enlivex Therapeutics Ltd简介
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
公司代码ENLV
公司Enlivex Therapeutics Ltd
CEOHershkovitz (Oren)
网址https://www.enlivex.com/
常见问题
Enlivex Therapeutics Ltd(ENLV)的当前股价是多少？
Enlivex Therapeutics Ltd(ENLV)的当前股价是 0.835。
Enlivex Therapeutics Ltd的股票代码是什么？
Enlivex Therapeutics Ltd的股票代码是ENLV。
Enlivex Therapeutics Ltd股票的52周最高点是多少？
Enlivex Therapeutics Ltd股票的52周最高点是2.100。
Enlivex Therapeutics Ltd股票的52周最低点是多少？
Enlivex Therapeutics Ltd股票的52周最低点是0.794。
Enlivex Therapeutics Ltd的市值是多少？
Enlivex Therapeutics Ltd的市值是20.28M。
Enlivex Therapeutics Ltd的净利润是多少？
Enlivex Therapeutics Ltd的净利润为-15.01M。
现在Enlivex Therapeutics Ltd(ENLV)的股票是买入、持有还是卖出？
根据分析师评级，Enlivex Therapeutics Ltd(ENLV)的总体评级为买入，目标价格为7.000。
Enlivex Therapeutics Ltd(ENLV)股票的每股收益（EPS TTM）是多少
Enlivex Therapeutics Ltd(ENLV)股票的每股收益（EPS TTM）是-0.551。
相关品种
